US Drug Regulators Set January Target to Decide on Approval of Pfizer’s COVID-19 Vaccine

Syringes with the COVID-19 Pfizer vaccine are pictured ready for use at a mobile clinic in Los Angeles, Calif., on July 9, 2021. Frederic J. Brown/AFP via Getty Images

A review of Pfizer’s request for approval of its COVID-19 vaccine will likely be completed by January 2022, U.S. drug regulators announced Friday.

The U.S. Food and Drug Administration (FDA) agreed to make the request a priority.